MabGenesis (653A) will be newly listed on 2 November. The company's potential, with the development of antibody drugs for pets at the core of its business, is attracting attention alongside its performance since the IPO offering date.
MabGenesis completed its new listing on 2 November and made its debut on the trading market under security code 653A.
The company develops antibody drugs for dogs and cats, and information on the business activities, peer companies and earnings of IPO companies is considered useful to readers in making investment decisions.